✦ LIBER ✦

PCN50 COST-MINIMIZATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXED AS A SECOND-LINE TRETAMENT OF ADVANCED NON-SMALL LUNG CANCER (NSCLC) IN THE CONDITIONS OF THE CZECH REPUBLIC

✍ Scribed by E Suchankova; T Doležal

Book ID: 119597437
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 69 KB
Volume: 11
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)66586-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN90 Cost-Effectiveness Analysis of Erl

PCN90 Cost-Effectiveness Analysis of Erlotinib Versus Docetaxel, Pemetrexed for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Russia

✍ Nguyen, T.T.T.; Yagudina, R.; Kulikov, A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PCN10 COST-EFFCTIVENESS ANALYSIS OF ERLO

PCN10 COST-EFFCTIVENESS ANALYSIS OF ERLOTINIB COMPARED WITH DOCETAXEL AND PEMETREXED FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN TAIWAN

✍ TC Hsia; GC Chang; YM Chen; MC Lin; WC Su; CM Tsai; CM Tsai; L Yang; J Creeden 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PCN25 COST-EFFECTIVENESS ANALYSIS OF ERL

PCN25 COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL AS A SECOND- OR THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN KOREA

✍ Kim, YG; Lee, EK 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

PCN32 COST-MINIMISATION ANALYSIS OF ERLO

PCN32 COST-MINIMISATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXEDAS SECOND-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER (NSCLC) FROM THE PERSPECTIVE OF A PRIVATE PAYER IN BRAZIL

✍ S Stefani; MG Saggia; EA Santos 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

PCN36 ECONOMIC EVALUATION OF ERLOTINIB,

PCN36 ECONOMIC EVALUATION OF ERLOTINIB, DOCETAXEL AND PEMETREXEDAS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). A COST-MINIMIZATION IN ITALIAN HOSPITALS

✍ S Capri; A Morabito; G Carillio; F Grossi; R Longo; G Cerea; F Rossetti 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Randomized Phase III Trial of Erlotinib

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

✍ Kawaguchi, T.; Ando, M.; Asami, K.; Okano, Y.; Fukuda, M.; Nakagawa, H.; Ibata, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 183 KB